A Pharmacokinetic Study to Compare Sino-implant (II) During Four Years of Use to Jadelle During Five Years of Use by Kenyan Women
Trial Snapshot
- Phase
- Not Applicable
- Status
- Withdrawn
- Sponsor
- FHI 360
- Locations
- 1
- Primary Endpoint
- Total and Free LNG concentrations in Jadelle users at Four Years and Sino-implant users at Five Years
Study Overview
Brief Summary
A cross-sectional study to compare pharmacokinetics of Sino-implant (II) during four years of used and Jadelle during five years of use by Kenyan women.
Detailed Description
A cross-sectional study to compare the pharmacokinetics of Sino-implant (II) during four years of use and Jadelle during five years of use by Kenyan women. The active ingredient in both implants is levonorgestrel (LNG) which is a synthetic progestin that has been used in combined oral contraceptives and in progestin-only pills for more than 30 years.
Population: A total of 280 women between the ages of 18 to 44 years who are currently using Sino-implant (II) or Jadelle contraceptive implants will be enrolled in one of six cohorts of women:
Cohort 1: (n=20 Sino-implant (II), n=20 Jadelle) women enrolled 1-3 months before their 6-month insertion anniversary.
Cohort 2: (n=20 Sino-implant (II), n=20 Jadelle) women enrolled 1-3 months before their 12-month insertion anniversary.
Cohort 3: (n=20 Sino-implant (II), n=20 Jadelle) women enrolled 1-3 months before their 24-month insertion anniversary.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to 44 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Have a Sino-implant (II) or Jadelle implant set in place, confirmed by physical exam;
- •Have a confirmed contraceptive implant insertion date consistent with the criteria for the cohort she is to be enrolled in;
- •Be aged between 18 and 44 years, inclusive;
- •Not wish to become pregnant in the next six months;
- •Not desire implant removal within the next six months.
- •Be able to understand the information given to them and to make personal decisions on whether to participate or not in the study;
- •Consent to participation, and sign an informed consent form;
- •Agree and be able to return to the clinic for the second study visit.
Exclusion Criteria
- •The following criteria exclude participation in the study:
- •Use of rifampicin, and/or anticonvulsants (barbiturates, phenytoin, phenobarbital, carbamazepine, oxcarbazepine, primidone, topiramate), and/or herbal products containing St. John's wort (Hypericum perforatum), by self-report;7
- •Use of medications containing LNG or other hormones that impact LNG or SHBG disposition, e.g. treatment with LNG or oral contraceptives for bleeding disturbances, by self-report;
- •Use of anti-retroviral drugs, by self-report;
- •Any condition (social or medical) which in the opinion of the Investigator would make study participation unsafe, would interfere with adherence to study requirements or complicate data interpretation.
Outcomes
Primary Outcomes
Total and Free LNG concentrations in Jadelle users at Four Years and Sino-implant users at Five Years
Time Frame: 6 months
Total and free LNG plasma concentrations measured at four years of Sino-implant (II)use and at five years of Jadelle use
Secondary Outcomes
- Total and Free LNG concentrations at Four Years of Jadelle and Sino-implant Use(6 months)
- Total and free LNG plasma concentration-time profiles at 4 years following Sino-implant (II) and at over 5 years following Jadelle insertion(6 months)
- SHBG serum concentration-time profile over 4 years following Sino-implant (II) and over 5 years following Jadelle insertion.(6 months)